Accelerating precision medicine trials in prostate cancer

This call is now closed.

One of our major aims over the next ten years is to improve treatments for men with prostate cancer. A key element in improving treatments will be to move away from the current selection of treatments on a blunt one-size-fits-all basis which is ineffective for many men to an approach that is based on stratifying men to different treatments depending on the driving characteristics of their particular cancer.

Prostate cancer still lags behind other cancers, where large scale multi-arm precision medicine trials are up and running and look set to make precision care the standard way of treating those cancers rather than an exception to the norm. We are determined to close this gap as quickly as possible because rational matching of treatment to individual cancer drivers will give men with prostate cancer more chance of surviving the disease for longer. Precision care should also reduce the number of men wasting time on, and suffering debilitating side effects from, treatments that will never work for them, and instead focus on giving the treatments with the greatest chance of success. Finally, more rational and effective use of treatments in this way will improve the cost/benefit ratio for the NHS.

Our vision is that numerous precision medicine approaches, rationally matching treatment (or treatments) to measurable biomarkers, should be available for men with advanced prostate cancer. These approaches could be delivered either through multiple individual trials or through one or more large scale multi-arm trials similar to the National Lung MATRIX trial or the FOCUS4 trial in colorectal cancer.

Through this funding call we aim to accelerate the progression of as many precision medicine approaches into clinical trials (and thus into clinical practice) as possible.

Application Process

Applications must be made by the Principal Investigator and using our online Prostate Cancer UK CC Grant Tracker system. Please be sure to read the accompanying Guidance notes for this scheme for further details about completing the online form. The application process consists of a single application period.

  • Applications received will first be validated by the Research Team at Prostate Cancer UK to eliminate those which do not meet the basic eligibility criteria for this call.
  • Applications will be peer reviewed by at least three independent referees (in accordance with AMRC guidelines).
  • Shortlisted applicants will then be assessed by representatives of our Research Advisory Committee and co-opted members with particular expertise needed to assess applications to this call.  

Final funding decisions will be made before the end of March 2017. All awards are subject to our standard terms and conditions. Please note that these terms are subject to change.

Prostate Cancer UK – STHLM3 UK Validation

This call is now closed.

STHLM3 was a prospective, population-based study conducted in Stockholm, Sweden, which set out to determine whether a new test (called STHLM3) is more accurate at diagnosing prostate cancer than PSA. The results of this study were extremely exciting and suggested that it has the potential to reduce unnecessary biopsies without compromising the ability to diagnose Gleason Score ≥7 prostate cancer.

However, there is a need to validate the findings of this trial in a UK-representative population and to test the feasibility of applying this diagnostic test at scale through normal NHS provision.

We are calling for proposals from the research community to prospectively validate the exciting results of the STHLM3 study in a UK setting. Please read our accompanying guidance document to find out more and follow the link below to apply now.


Application Process

Applications must be made by the Principal Investigator and using our online Prostate Cancer UK CC Grant Tracker system. Please be sure to read the accompanying Guidance notes for this scheme for further details about completing the online form.

The application process consists of a single application period.

  • Applications received will first be validated by the Research Team at Prostate Cancer UK to eliminate those which do not meet the basic eligibility criteria for this call.
  • Applications will be peer reviewed by at least three independent referees (in accordance with AMRC guidelines).
  • Shortlisted applicants will then be invited to be interviewed by representatives of our Research Advisory Committee.

Final funding decisions will be made by the end of September 2016.

All awards are subject to our standard terms and conditions. Please note that these terms are subject to change.